We had the pleasure of speaking with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the use of venglustat in the treatment of patients with Parkinson’s Disease, and the Phase 2 MOVES-PD study results.
Part 1 of our discussion can be viewed here.
The abstract entitled ‘Venglustat in Parkinson’s Disease Patients with a GBA Mutation: Results from Part 2 of the Phase 2 MOVES-PD Trial’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
Questions:
- Could you tell us a little about the MOVES-PD clinical trial and its findings? (0:14)
- Why do you think the study failed to meet its endpoints, and what can we learn from this failure? (2:38)
- Is there a role for venglustat in the future treatment of Parkinson’s disease? (3:27)
Disclosures: Tanya Simuni has served as a consultant for Acadia, Denali, General Electric (GE), Neuroderm, Sanofi, Sinopia, Sunovion, Roche, Takeda, MJFF and Voyager; has served on the advisory board for Acadia, Denali, General Electric (GE), Sunovian, Roche; has served as a member of the scientific advisory board of Neuroderm and Sanofi. Tanya Simuni has received research funding from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Amneal, Prevail, UCB, NINDS, MJFF and Parkinson’s Foundation.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
